相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。LncRNA MALAT I Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway
Qingqiang Dai et al.
CANCER MANAGEMENT AND RESEARCH (2020)
The expression of lncRNA-MALAT1 in breast cancer patients and its influences on prognosis
Zhenxuan Sun et al.
CELLULAR AND MOLECULAR BIOLOGY (2020)
Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer
Liuhong Zheng et al.
BIOSCIENCE REPORTS (2019)
Markers of Cancer Cell Invasion: Are They Good Enough?
Tatiana S. Gerashchenko et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Evaluation of Angiogenesis Assays
Zachary I. Stryker et al.
BIOMEDICINES (2019)
LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
Zhixian Fang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival
Zhanwei Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway
Lin Bai et al.
EXPERIMENTAL CELL RESEARCH (2018)
Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling
Debottam Sinha et al.
FASEB JOURNAL (2018)
Circulating long non-coding RNA MALAT1 expression as molecular biomarker in Egyptian patients with breast cancer
Haidy E. Zidan et al.
CANCER GENETICS (2018)
Long noncoding RNA MALAT1 suppresses breast cancer metastasis
Jongchan Kim et al.
NATURE GENETICS (2018)
LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway
Yong Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Peilong Li et al.
MOLECULAR CANCER THERAPEUTICS (2017)
LncRNA-mediated regulation of cell signaling in cancer
W-X Peng et al.
ONCOGENE (2017)
FOXO1-MALAT1-miR-26a-5p Feedback Loop Mediates Proliferation and Migration in Osteosarcoma Cells
Juntao Wang et al.
ONCOLOGY RESEARCH (2017)
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss
Gayatri Arun et al.
GENES & DEVELOPMENT (2016)
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
JOURNAL OF CLINICAL ONCOLOGY (2016)
MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10
Ying Qi et al.
ONCOTARGET (2016)
The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration
Yanqing Zhou et al.
PLOS ONE (2016)
The emerging role of IncRNAs in cancer
Maite Huarte
NATURE MEDICINE (2015)
Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer
Er-Jun Pang et al.
TUMOR BIOLOGY (2015)
Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice
Yanyuan Wu et al.
BMC CANCER (2014)
RNA-RNA Interactions Enable Specific Targeting of Noncoding RNAs to Nascent Pre-mRNAs and Chromatin Sites
Jesse M. Engreitz et al.
CELL (2014)
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
Jason A. West et al.
MOLECULAR CELL (2014)
Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer
Fubo Wang et al.
ONCOTARGET (2014)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
Yanyuan Wu et al.
PLOS ONE (2013)
Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition
Liang Ying et al.
MOLECULAR BIOSYSTEMS (2012)
Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells
Yanyuan Wu et al.
MOLECULAR CANCER RESEARCH (2012)
Malat1 is not an essential component of nuclear speckles in mice
Shinichi Nakagawa et al.
RNA (2012)
The lncRNA Malat1 Is Dispensable for Mouse Development but Its Transcription Plays a cis-Regulatory Role in the Adult
Bin Zhang et al.
CELL REPORTS (2012)
Interplay between FOXO, TOR, and Akt
Nissim Hay
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins
Guri Tzivion et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion
Haijun Zhang et al.
CANCER RESEARCH (2011)
FOXO1A Is a Target for HER2-Overexpressing Breast Tumors
Yanyuan Wu et al.
CANCER RESEARCH (2010)
Prognostic Significance of Phosphorylated FOXO1 Expression in Soft Tissue Sarcoma
Binglin Zhang et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Evolution and Functions of Long Noncoding RNAs
Chris P. Ponting et al.
CELL (2009)
Long non-coding RNAs: insights into functions
Tim R. Mercer et al.
NATURE REVIEWS GENETICS (2009)
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
AJ Clayton et al.
BRITISH JOURNAL OF CANCER (2004)
MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer
P Ji et al.
ONCOGENE (2003)
Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion
G Rena et al.
EMBO JOURNAL (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
O Stål et al.
ANNALS OF ONCOLOGY (2000)
分享论文
